EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Interaction of Camptothecin Anticancer Drugs with Ribosomal Proteins L15 and L11: A Molecular Docking Study

Christian Bailly iD, Gérard Vergoten iD

Molecules · 2023

DOI: 10.3390/molecules28041828 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Christian Bailly und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institut de Chimie Pharmaceutique Albert Lespagnol (ICPAL), Faculté de Pharmacie, University of Lille, 3 rue du Professeur Laguesse, BP-83, F-59006 L…. Hauptthemen laut MEDLINE: DNA Topoisomerases, Type I, Antineoplastic Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The antitumor drug topotecan (TPT) is a potent inhibitor of topoisomerase I, triggering DNA breaks lethal for proliferating cancer cells. The mechanism is common to camptothecins SN38 (the active metabolite of irinotecan) and belotecan (BLT). Recently, TPT was shown to bind the ribosomal protein L15, inducing an antitumor immune activation independent of topoisomerase I. We have modeled the interaction of four camptothecins with RPL15 derived from the 80S human ribosome. Two potential drug-binding sites were identified at Ile135 and Phe129. SN38 can form robust RPL15 complexes at both sites, whereas BLT essentially gave stable complexes with site Ile135. The empirical energy of interaction (ΔE) for SN38 binding to RPL15 is similar to that determined for TPT binding to the topoisomerase I-DNA complex. Molecular models with the ribosomal protein L11 sensitive to topoisomerase inhibitors show that SN38 can form a robust complex at a single site (Cys25), much more stable than those with TPT and BLT. The main camptothecin structural elements implicated in the ribosomal protein interaction are the lactone moiety, the aromatic system and the 10-hydroxyl group. The study provides guidance to the design of modulators of ribosomal proteins L11 and L15, both considered anticancer targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA Topoisomerases, Type IAntineoplastic AgentsHumansMolecular Docking SimulationCamptothecinRibosomal ProteinsTopotecanDNATopoisomerase I Inhibitors

Stichwörter der Autor:innen

anticancer agentsbelotecancamptothecinmolecular dockingribosomal proteintopoisomerase Itopotecan

Substanzen

DNA Topoisomerases, Type Iribosomal protein L15CamptothecinAntineoplastic AgentsRibosomal ProteinsTopotecanDNATopoisomerase I Inhibitors

Autor:innen und Institutionen

  • Institut de Chimie Pharmaceutique Albert Lespagnol (ICPAL), Faculté de Pharmacie, University of Lille, 3 rue du Professeur Laguesse, BP-83, F-59006 Lille, France.
  • CNRS, Inserm, CHU Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, University of Lille, F-59000 Lille, France.
  • OncoWitan, Consulting Scientific Office, Wasquehal, F-59290 Lille, France.

ORCID-Profile: Christian Bailly, Gérard Vergoten

Zitieren

APA

Bailly, C., & Vergoten, G. (2023). Interaction of Camptothecin Anticancer Drugs with Ribosomal Proteins L15 and L11: A Molecular Docking Study. Molecules. https://doi.org/10.3390/molecules28041828

Vancouver

Bailly C, Vergoten G. Interaction of Camptothecin Anticancer Drugs with Ribosomal Proteins L15 and L11: A Molecular Docking Study. Molecules. 2023. doi:10.3390/molecules28041828

BibTeX
@article{Bailly2023,
  author = {Bailly, Christian and Vergoten, Gérard},
  title = {Interaction of Camptothecin Anticancer Drugs with Ribosomal Proteins L15 and L11: A Molecular Docking Study},
  journal = {Molecules},
  year = {2023},
  doi = {10.3390/molecules28041828}
}
Kostenlos starten →